Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TTR | P02766 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | DHODH | Q02127 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25392363 | 0.89 | LMNA (0.76) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL13299182 | 0.88 | LMNA (0.65) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL4507009 | 0.88 | LMNA (0.65) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL12179964 | 0.88 | TP53 (0.57) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL23423499 | 0.87 | HTT (0.57) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL11521452 | 0.87 | LMNA (0.67) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL3807352 | 0.87 | PDE4D (0.64) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL11366904 | 0.86 | LMNA (0.63) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL13653030 | 0.85 | LMNA (0.74) | LMNACYP1A2CYP3A4CYP2C9MEN1 | |
| SCHEMBL26742261 | 0.85 | HTT (0.56) | LMNAMEN1PKMNFKB1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-02 | — | — | US | disclosed |
| WO-2021188296-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2021-09-23 | — | — | WO | disclosed |
| US-5760034-A | ANTIALLERGEN, ANTIINFLAMMATORY, ANTIULCER | SCHERING CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0505434-A1 | HETEROCYCLIC SUBSTITUTED NAPHTHYRIDINONES AND METHODS AND COMPOSITIONS EMPLOYING THEM | SCHERING CORPORATION (US) | 1992-09-30 | — | — | EP | disclosed |
| WO-1991008208-A1 | HETEROCYCLIC SUBSTITUTED NAPHTHYRIDINONES AND METHODS AND COMPOSITIONS EMPLOYING THEM | SCHERING CORPORATION (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | XDH, PNPO, PNP | LMNA 1038/4885CYP1A2 785/4885CYP3A4 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.